// App-Quantinova.ai

LB.01.02 : PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV

Researchers

Presenter

  • Schmieder, R.E

Principal Investigators

  • Ott, C

  • Toennes, S

  • Gertner, M

  • Dawood, O

  • Saxena, M

  • OBrien, B

  • Lobo, M

Medical Centers

  • Department of Nephrology and Hypertension, University Hospital of the Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

  • Institute of Legal Medicine, Forensic Toxicology Department, Goethe University, Frankfurt/main, Germany

  • CEO, Kona Medical, Department of Surgery, Stanford School of Medicine, Stanford, United Kingdom

  • CMO, Kona Medical, Bellevue, Washington, DC, USA

  • NIHR Barts Cardiovascular Biomedical Research Unit, William Harvey Research Institute, London, United Kingdom

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multinational

  • Prospective

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved